You are here

Development of a tool to examine proteomic pathways in the AD brain

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AG067855-01
Agency Tracking Number: R41AG067855
Amount: $251,944.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIA
Solicitation Number: PAS19-317
Timeline
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-06-01
Award End Date (Contract End Date): 2020-11-30
Small Business Information
34 BRYAN RD
Branford, CT 06405-4504
United States
DUNS: 117159387
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ERIK GUNTHER
 (203) 785-4979
 erik.gunther@yale.edu
Business Contact
 ERIK GUNTHER
Phone: (203) 430-4187
Email: erik.gunther@yale.edu
Research Institution
 YALE UNIVERSITY
 
OFFICE OF SPONSORED PROJECTS, PO BOX 208327
NEW HAVEN, CT 06520-8327
United States

 Nonprofit college or university
Abstract

Abstract
For the extent of our careers as Alzheimer’s researchers, we have struggled with the limitations
imposed by the standard techniques for protein analysis. Western blot, the go-to protein
technology of the bench researcher, is no match for the complex brain protein distortions of AD.
To remedy this debility, we devised a technology that we are making available to all researchers
through the company we founded, ProteoWise Inc. ProteoWise is engineering an instrument
that will provide the same protein relative concentration and molecular weight information of
Western blot, 10 x faster, 10 x cheaper, using 10x less sample, and, critically, will provide
unlimited multiplexed proteomic data per sample. To meet the promise of this technology, we
invented micro polyacrylamide electrophoresis (mPAGE), a process we seek to optimize with
the support applied for here. When complete, this instrument will not only make our AD research
more successful, it will empower AD research around the world in our battle against this enemy.Narrative
The plague of Alzheimer’s will not be stopped until we develop deep enough understanding of
the disease to design drugs against its underlying mechanisms. Alzheimer’s researchers know it
is a disease of brain proteins. ProteoWise has miniaturized polyacrylamide gel electrophoresis
(mPAGE), which will bring high-throughput, low-cost, benchtop proteomics to the Alzheimer’s
researcher for therapeutic drug discovery applications.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government